Thrombotic events – Page 10 – Communicable Diseases Research

Blood test dynamics in hospitalized COVID-19 patients: Potential utility of D-dimer for pulmonary embolism diagnosis

Research Article

Published on 2020-12-282022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS,

D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients

Article

Published on 2020-12-242022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

COVID-19 환자의 숙주 혈전 염증 반응 조절에 대한 무작위, 공개, 적응, 개념 증명 임상 시험: DAWn-Antico 연구

Randomized Controlled Trial

Published on 2020-12-092022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] Activation adaptive added Anakinra Aprotinin bradykinin cellular entry Clinical improvement clinical status clinical trial Coagulation Combination complications Contact country COVID-19 COVID-19 disease COVID-19 pandemic D-dimer defined develop Disease progression dose drug effective EU Clinical Trial EU Clinical Trials fibrinolysis heparin heparins high mortality hospitalized COVID-19 patients Host hyperinflammation ICU in vitro incidence Infection inflammatory parameters Inflammatory response information inhibitor inhibitory effect initial intensive care Intervention investigated Kallikrein local inflammatory response low molecular weight Low molecular weight heparins marker modulate modulation multicenter Open-label Ordinal Scale outcome pathophysiological pathway Patient Primary outcome Prognostic factor proof-of-concept clinical trial Randomized randomized clinical trial reached receptor receptor antagonist reduce regimen SARS-CoV-2 second wave severe COVID-19 severe COVID-19 disease shown standard thromboprophylaxis supplementary material the WHO Thromboinflammatory response thrombotic Thrombotic complications Thrombotic events Trial Trial registration vaccination Viral viral replication WHO ordinal scale
[DOI] 10.1186/s13063-020-04878-y PMC 바로가기 [Article Type] Randomized Controlled Trial

Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies

COVID-19 중증 환자에서 중간 용량 대 표준 용량 예방적 항응고제 및 스타틴 요법 대 위약: INSPIRATION/INSPIRATION-S 연구의 이론적 근거 및 설계

Article

Published on 2020-12-012022-09-11
Journal: Thrombosis research [Category] 임상,

[키워드] all-cause mortality Analysis anticoagulation antithrombotic therapy Arterial thrombosis atorvastatin bleeding Chain Reaction cohorts Composite Controlled trial coronavirus disease Coronavirus disease 2019 COVID-19 death double-blind eligibility criteria Enrollment Exploratory analyses Exploratory analysis extracorporeal membrane oxygenation factorial design hallmark hallmarks help hypothese Hypothesis immune response include independent inferiority inspiration intensity intention-to-treat intermediate limit liver enzyme liver enzymes major bleeding management manifestation matching placebo modified intention-to-treat Myopathy non-inferiority non-inferiority margin normal limit Odds ratio open open label Patient patients with COVID-19 per-protocol performed Placebo Platelet Platelet count polymerase chain polymerase chain reaction Prevent primary endpoint Prophylactic prophylactic anticoagulation question randomization Randomized Randomized controlled trial rationale Result reverse transcription reverse transcription polymerase chain reaction safety endpoint screened secondary endpoint Standard dose Standard-dose statin Stratified randomization subgroup tested therapy thrombocytopenia thrombosis thrombotic event Thrombotic events undergo Venous Thromboembolism Ventilator-free days VTE
[DOI] 10.1016/j.thromres.2020.09.027 PMC 바로가기 [Article Type] Article

D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review

정맥 혈전 색전증이 의심되는 COVID-19 환자의 D-이량체, 피브리노겐 및 IL-6: 내러티브 검토

Review

Published on 2020-11-132022-09-10
Journal: Vascular Health and Risk Management [Category] MERS, 바이오마커,

[키워드] activated acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus aPTT ARDS China Coagulation Coagulopathy coronavirus coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 patient COVID-19 patients critical COVID-19 patient critical COVID-19 patients Critically ill critically ill patients Cytokine storm D-dimer D-dimers Deep vein Deep vein thrombosis Degradation develop Disease progression Disseminated intravascular coagulation District DVT early diagnosis elevated Evidence evidence of Fever FIBRIN fibrin degradation products fibrinogen Fibrinogen levels global pandemic Health Organization heparin highlighting hyperactivity IL-6 include interleukin interleukin-6 intravascular coagulation Laboratory parameters lethargy LMWH low molecular weight low molecular weight heparin manifestation Mortality multiple organ failure narrative Organ failure Platelets Prognostic factor Prophylaxis prothrombin Prothrombin time Pulmonary embolism reducing respiratory respiratory distress review risk SARS-CoV-2 Seafood severe acute respiratory syndrome Coronavirus shown stages Suspected syndrome THROMBOPLASTIN Thromboprophylaxis thrombosis Thrombosis prophylaxis thrombotic thrombotic event Thrombotic events Treatment upper respiratory symptom upper respiratory symptoms Venous Thromboembolism VTE West WHO World Health Organization
[DOI] 10.2147/VHRM.S280962 PMC 바로가기 [Article Type] Review

Haematological manifestations of COVID-19: From cytopenia to coagulopathy

COVID-19의 혈액학적 징후: 혈구감소증에서 응고병증까지

Review

Published on 2020-11-012022-09-11
Journal: European journal of haematology [Category] SARS, 바이오마커,

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

COVID-19의 내피 손상 및 혈전성 미세혈관병증: 렉틴 경로 억제제 나르소플리맙으로 치료

Article

Published on 2020-11-012022-09-11
Journal: Immunobiology [Category] SARS, 진단, 치료법,

[키워드] activate Activation acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome Adverse drug reaction Adverse drug reactions anticoagulant effects ARDS Arterial thrombosis Autopsies baseline bind C-reactive protein C-reactive protein (CRP circulating compassionate use complement Complement activation complications Continuous Positive Airway Pressure control group Coronavirus-2 COVID-19 COVID-19 patient CPAP CRP during treatment effective Endothelial cell endothelial cell damage endothelial damage endothelial injury enzyme human immunoglobulin IgG4 IL-6 IL-8 Immunoglobulin Inflammation inhibit inhibitor Injury interleukin interleukin-6 interleukin-8 intubation Lactate lactate dehydrogenase LDH lectin lectin pathway life-threatening Lung injury mannan MASP-2 monoclonal antibody Mortality Narsoplimab nucleocapsid protein pathogenic Patient positive airway pressure reducing reduction reported respiratory respiratory distress Respiratory distress syndrome resulting retrospective SARS-CoV-2 Serine serine protease serum Serum IL-6 Serum level serum levels Severe acute respiratory syndrome severe acute respiratory syndrome-associated coronavirus-2 significantly higher survived sustained syndrome thrombosis thrombotic thrombotic event Thrombotic events thrombotic risk treat Treatment treatment for COVID-19 was used were assessed were used
[DOI] 10.1016/j.imbio.2020.152001 PMC 바로가기 [Article Type] Article

Incidence of Thrombotic Events and Outcomes in COVID-19 Patients Admitted to Intensive Care Units

Internal Medicine

Published on 2020-10-212022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] African American African Americans age analyzed Care Caucasian cause Complication coronavirus disease COVID-19 COVID-19 patients Critically ill Critically ill patient cumulative database develop Diagnosis event Evidence false discovery rate females healthcare ICU ICU patient incidence intensive care intensive care unit male material median median age medical record men Mortality mortality rate multiple comparisons Myocardial Older organization outcomes overall mortality Patient patients platform ranged reported Research Result risk factor severe COVID-19 severe disease shown significantly more statistically significant stroke study population thrombosis Thrombotic complications thrombotic event Thrombotic events Venous Thromboembolism VTE while women
[DOI] 10.7759/cureus.11079 PMC 바로가기 [Article Type] Internal Medicine

Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

COVID-19의 항인지질 항체는 항인지질 증후군에서 검출되는 항체와 다릅니다

Immunology

Published on 2020-10-152022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료기술,

[키워드] β₂-glycoprotein I activated Anti-phospholipid antibodies antibodies antibody Anticoagulant anticoagulation aPTT association Autoimmunity C reactive protein chemiluminescence Coagulopathy coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients Critically ill Critically ill patient critically ill patients death detectable develop domain ELISA epitope epitope specificity evaluate GPI hypercoagulable Hypercoagulable state investigated large cohort leads Lupus lupus anticoagulant objective Organ failure Patient patients Prevalence prothrombin reported Result sera severe COVID-19 specificity syndrome tested thrombosis thrombotic Thrombotic events were used
[DOI] 10.3389/fimmu.2020.584241 PMC 바로가기 [Article Type] Immunology

Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study

Article

Published on 2020-09-242022-10-28
Journal: Biology [Category] COVID-19,

[키워드] Acute respiratory failure addition Admission affected age Analysis Anticoagulant anticoagulation Antithrombotic average bleeding caused clinical suspicion Coagulopathy complications condition correlation COVID-19 D-dimer decrease Deep vein thrombosis diagnosed different dose dose doses drug drugs Efficacy enrolled evaluate Hemorrhagic High dose hospital Hospitalization hospitalized patients ICU increased risk intensive care Laboratory analysis life-threatening lower limb Mechanical men Patient patients performed Pneumonia Population positive pressure ventilation Prevalence Prevent Primary outcome Prophylaxis Prospective protocols pulmonary angiography reported Respiratory failure risk SARS-CoV-2 screened secondary outcome simple statistically Support target tested therapeutic Thromboembolic event Thromboembolic events Thromboprophylaxis thrombosis Thrombotic complications thrombotic event Thrombotic events thrombotic risk treated Venous Thromboembolism Ventilation women
[DOI] 10.3390/biology9100310 PMC 바로가기 [Article Type] Article